11 April marks another important date in this continuing story, as this is when the REACH Committee will discuss classification and potential labelling of the substance.
The socio-economic analysis, in its current form, does not paint the whole picture. And it is absolutely necessary for the EU Commission to see the whole picture when deciding on whether or not to grant an authorisation. Otherwise, this procedure threatens to counteract the very aim of REACH.
Two legislative never-ending stories regarding authorisation to use of the cancer-causing chemical chromium trioxide are finally coming to an end. Two applications – one from the company Gerhardi and one from a whole slew of companies spearheaded by chemical manufacturer Lanxess – got the REACH Committee’s green light last week to continue using chromium trioxide in a wide range of products.
74 percent of substances where a concern for human health and the environment has been demonstrated has not received any regulatory follow-up to control the risk and are still allowed on the EU market, says new report.
The European Court of Justice (ECJ) stated that the phthalate DEHP should be identified as an endocrine disruptor (EDC) for the environment in a ruling on January 23, 2019.
Last year we saw the finalisation of the phase in registration process in REACH. In May, the last registration deadlines expired, officially ending the phase-in period. So what have the costs amounted to?
The turn of the year is approaching fast and all over the world media outlets are reviewing the year that went by.
Who says chemicals can’t be interesting? Not us, anyway.
So without further ado, here’s ChemSec’s year in review, listing some memorable events of 2018.
Today, the European Parliament voted on the matter in plenary, and a great majority voted in favour of a resolution – in other words, against granting an authorisation.